Navigation Links
AMG 277 Discriminates Against S1P3 Receptor by 50-fold. S1P1 Lead Compounds Will Be Offered for Sale at a December 8, 2011 Sealed Bid Sale. Assets Generated by Epix Pharmaceuticals, Inc. and Amgen.
Date:11/29/2011

WELLESLEY HILLS, Mass., Nov. 29, 2011 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn") Assignee for the Benefit of Creditors of Epix Pharmaceuticals, Inc. ("Epix") announced today that AMG 277 discriminates against S1P3 receptor by 50-fold and that the S1P1 lead compounds will be offered December 8, 2011 in a sealed bid sale.  These assets were generated by Epix Pharmaceuticals, Inc. and Amgen.

AMG 277 has 57-nM functional EC50 for hS1P1 receptor and discriminates against S1P3 receptor by 50-fold.  It displayed efficacy in a DTH model with ED70 of 1.0 mpk.  AMG 277 was tested in FIH-enabling toxicology studies.    

Assets included in the sale include preclinical and toxicology data related to AMG 277, AMG 369 and six backup compounds, existing inventory of these compounds (API), and related patent portfolio.

Persons interested in bidding must sign a Confidentiality Disclosure Agreement ("CDA") obtained from Finn's office – jffinnjr@finnwarnkegayton.com or 781-237-8840; upon receipt of the executed CDA, applicants will receive a bid package, to be completed and returned by December 8, 2011.

About Joseph F. Finn, Jr., C.P.A.

Joseph F. Finn, Jr., C.P.A. is the founding partner of the firm, Finn, Warnke & Gayton, LLP Certified Public Accountants of Wellesley Hills, Massachusetts.  He works primarily in the area of management consulting for distressed enterprises, bankruptcy accounting and related matters, such as assignee for the benefit of creditors and liquidating agent for a corporation.  His most recent Assignments for the Benefit of Creditors in the biotech filed include Spherics, Inc., ActivBiotics, Inc., Prospect Therapeutics, Inc. and Source MDx.

For further information, please contact Joseph F. Finn, Jr., C.P.A. at 781-237-8840 or jffinnjr@finnwarnkegayton
'/>"/>

SOURCE Joseph F. Finn, Jr., C.P.A.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
2. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
3. Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria
4. Molnlycke Drives Home the Fight Against Staph and Other MRSA Infections
5. Mayo Clinic Study Finds FDA Warning Against Anti-Nausea Drug Droperidol Unnecessary
6. Targeted Nanoparticles Offer Promise in the Battle Against Cancer
7. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
8. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
9. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
10. Semafores PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents
11. BD and PEPFAR Collaborate to Strengthen Laboratory Systems in Fight Against HIV/AIDS and TB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... July 22, 2014  Halozyme Therapeutics, Inc. (NASDAQ: ... enrollment and dosing of patients in its ongoing Phase ... pancreatic cancer under the revised clinical protocol agreed to ... PEGylated form of Halozyme,s proprietary recombinant human hyaluronidase under ... hyaluronan. "Our diligent effort to rapidly ...
(Date:7/22/2014)... -- ConvaTec, a privately-held medical products and technologies company, today ... chief financial officer of the company, effective July 22, ... president and chief financial officer of Elan Corporation, a ... was part of a senior team that helped build ... to Perrigo, a pharmaceutical manufacturer, in December 2013. ...
(Date:7/22/2014)... , July 22, 2014  UL (Underwriters ... that the U.S. Food and Drug Administration (FDA) ... consensus standards for medical devices incorporating lithium or ... - Standard for Household and Commercial Batteries, and ... Consensus standards are standards recognized ...
Breaking Medicine Technology:Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 2Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 3ConvaTec Names Nigel Clerkin Chief Financial Officer 2Two UL Battery Safety Standards Are now FDA Recognized Consensus Standards for Medical Devices 2
... HARBIN, China , July 7 /PRNewswire-Asia-FirstCall/ -- Renhuang,Pharmaceuticals, ... and distributor of botanical products,bio-pharmaceuticals and traditional Chinese medicines ("TCM"), today announced,that, ... on the NYSE Amex,Market under the ticker symbol "CBP". , ... On this occasion, ...
... , SOMERVILLE, N.J. , July 7 ... surgical care, announced today the introduction of ETHICON™ ... designed to achieve adjunctive hemostasis (stoppage of bleeding) ... leakage. The US Food and Drug Administration (FDA) ...
Cached Medicine Technology:Renhuang Begins Trading on NYSE Amex 2Renhuang Begins Trading on NYSE Amex 3Renhuang Begins Trading on NYSE Amex 4Ethicon, Inc. Expands Hemostasis Product Portfolio with Approval of the Company's First Synthetic Internal Use Sealant 2Ethicon, Inc. Expands Hemostasis Product Portfolio with Approval of the Company's First Synthetic Internal Use Sealant 3
(Date:7/22/2014)... July 22, 2014 University of ... officially opened the doors of its state-of-the-art, $151 million ... the heart of downtown San Francisco's South of Market ... patients a year. Those patients will now be greeted ... iKiosks . , Advanced Kiosks engineering team ...
(Date:7/22/2014)... of the deadly MERS virus were detected in the air ... new study says. The findings show the need for ... can be transmitted through the air, the researchers said. ... camel barn owned by a 43-year-old male MERS patient who ... man later died. One of the camels in the barn ...
(Date:7/22/2014)... stimulation treatments, like electroconvulsive therapy (ECT) and transcranial ... treatment of depression. Like antidepressant medications, however, they ... patient may receive several weeks of regular ECT ... Thus, there is an impetus to develop antidepressant ... field magnetic stimulation (LFMS) is one such potential ...
(Date:7/22/2014)... The “Human Insulin Market by Product Type ... Human Insulin (Rapid Acting, Long Acting, Premixed)], by ... - Forecast to 2019” provides a detailed overview ... market trends, and strategies impacting the global human ... of the revenue and share analysis. , Browse ...
(Date:7/22/2014)... 22, 2014 Cloud+MD Office 2.0 ... interoperable suite of medical software and services, designed ... providers, that produces “Actionable Information” to help Independent ... Systems and Billing Services optimize a wide range ... Quality, Greater Efficiency, Noticeable Cost Reductions and Better ...
Breaking Medicine News(10 mins):Health News:iKiosks Are Gateway to Premier Dental Facility 2Health News:iKiosks Are Gateway to Premier Dental Facility 3Health News:MERS Virus Found in Air in Camel Barn 2Health News:Low strength brain stimulation may be effective for depression 2Health News:Human Insulin Market Worth $42 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Human Insulin Market Worth $42 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Human Insulin Market Worth $42 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Human Insulin Market Worth $42 Billion by 2019 - New Report by MarketsandMarkets 5Health News:Cloud-MD Software will soon Receive MU2 Certification 2
... ... tissue and muscle pain therapy called the Active Release Technique. Active Release Technique is ... ... downtown NYC office, noted local chiropractor, Dr. Steven Shoshany, has recently expanded his ...
... A team of American psychologists and neuroscientists have found ... Anorexia Nervosa, can be regained. The research, published in ... that through specialist treatment patients with this eating disorder ... Anorexia Nervosa (AN) is a serious psychiatric ...
... ... MBA HealthGroup partner to increase physician adoption of electronic health records statewide , ... (PRWEB) May 26, 2010 ... Vermont, announced today that Vermont Information Technology Leaders, Inc. (VITL), the non-profit ...
... ... of Medical Services That Wastes Over 20 Cents of Every Dollar Spent , ... Lexington, MA (PRWEB) May 26, 2010 -- ... which are pivotal to the national healthcare debate, in the May issue of the ...
... ... DSPanel today announced the availability of their latest ... DSPanel announced the availability of DSPanel Performance Canvas 2.2 with Planning, ... designed to be used as an accompaniment to Sharepoint 2010 and ...
... ... to prescription sunglasses , ... New Jersey (PRWEB) May 26, 2010 -- With summer quickly approaching, GlassesUSA.com getting ... prescription glasses has been selling prescription sunglasses since the store opened. ...
Cached Medicine News:Health News:NYC Chiropractor Expands Practice with Therapy for Muscle and Overuse Injuries 2Health News:Brain volume found to change following weight gain in adults with anorexia 2Health News:MBA HealthGroup Selected as Preferred Partner by VITL 2Health News:HealthMETRICS Partners, Inc. Article in AJMC Outlines Innovative Approach to Combat Rising Healthcare Costs 2Health News:DSPanel's New Mobile Analytics Server for Business Intelligence: Data Analysis, Monitoring and Planning When and Where You Need It 2Health News:DSPanel's New Mobile Analytics Server for Business Intelligence: Data Analysis, Monitoring and Planning When and Where You Need It 3Health News:GlassesUSA.com Launches Section for Prescription Sunglasses 2
Take Performance to a Higher Level....
Rapid Exchange Stent Delivery System...
The MULTI-LINK PIXEL Coronary Stent System was designed to address the challenges of small vessel treatment in patients with abrupt or threatened abrupt closure (ATC)....
... The EVS has an ergonomic ... activated mechanism which requires a ... gently locks onto the target ... the site before, during and ...
Medicine Products: